January 2023 – TargED is pleased to announce the appointment of Erik van den Berg as Chair of its Supervisory Board. Kristof Vercruysse, CEO of TargED commented: “We are honored to have Erik van den Berg join as independent Chair of the TargED Board. With… Read More »APPOINTED – Erik van den Berg as Chair of Board
September 2022 – TargED is proud to present the installment of a Scientific Advisory Board dedicated to the development of Microlyse for treatment of Acute Ischemic Stroke. This seperate advisory board consists of renowned preclinical and clinical experts in the field of ischemic stroke Its… Read More »APPOINTED – Scientific Advisory Board AIS
August 2022 – Blood journal has published an article demonstrating the effectivity of TargED’s lead compound, Microlyse, in two experimental Acute Ischemic Stroke (AIS) models.
TargED Biopharmaceuticals is very pleased to announce the appointment of Emile van Corven as their Vice President Chemistry Manufacturing & Control. Kristof Vercruysse, CEO commented: “In Emile, we found the ideal candidate to improve and standardize the production process of our lead compound, Microlyse.” Please… Read More »Emile van Corven appointed as Vice President Chemistry Manufacturing & Control (VP CMC)
July 2022 – We’re currently looking for a Scientific & Medical Writer to strengthen our team. Are you looking for a new challenge and do you match our profile? Please make sure to send us your CV + motivation letter.
TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate we’ll pursue our common goal: to bring Microlyse into clinical development! Read the press release here
January 2022 – Our new clot-buster Microlyse is now published in- and on the cover of Blood. You can: Listen to the Blood podcast (7:15 – 12:30) Download our paper here (before March 18, 2022) click to enlarge
June 2021 – TargED Biopharmaceuticals today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). With his extensive experience in the clinical development of new medical products, Ludo will support the company’s transition from preclinical to clinical stage company.
Again, we can share some thrilling news! TargED is awarded the @NWO Take Off II loan (€250.000) to further develop its clot-busting lead compound, Microlyse, which could ultimately help millions of patients around the globe. What a welcome reward to a remarkable year 2020! See… Read More »TargED is granted the NWO Take Off II loan
November 24th, 2020 – We are very proud to announce the closing of a €1.35m Seed investment from Curie Capital, Utrecht Health Seed Fund and Fonds InvesteringsRijpe STarts (FIRST), supported by additional funding from Health Holland. Pleas find the full press release attached!